Targeting SERPINB3-MAPK axis-mediated cuproptosis resistance enhances the response to antitumor immunotherapy.
Huang XX, Xie CK, Mo YC, Li W, Wu YD, Li ZY, Zhang HX, Li G, Jin L, Lin XQ, Hu JF, Chen YH, Lin HY, Zhu SC, Lu JP, Zhu HJ, Wang WW, Huang Y, Wang ZW, Huang L, Wang DF, Tian YF, Liao CY, Chen S.
Huang XX, et al. Among authors: lin xq.
Mol Cancer. 2025 Nov 22. doi: 10.1186/s12943-025-02529-x. Online ahead of print.
Mol Cancer. 2025.
PMID: 41275193
Free article.